Allergic Rhinitis Market Size in the 7MM was ~USD 10,400 Million in 2023, it is expected to grow by 2034, estimates DelveInsight

The allergic rhinitis market was valued at approximately USD 10,400 million in 2023 and is expected to grow at a strong compound annual growth rate (CAGR) over the forecast period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Allergic Rhinitis landscape.

In 2023, the United States accounted for the largest share of the allergic rhinitis market within the 7MM, with a market value of approximately USD 3,600 million, and is expected to continue growing through 2034. Among European countries, Germany led the market with a valuation of USD 1,358 million, while Spain represented the smallest market at USD 604 million. Meanwhile, Japan’s allergic rhinitis market was estimated at around USD 2,347 million in 2023, accounting for nearly 23% of the total 7MM market.

The expected introduction of novel allergic rhinitis therapies, such as REGN5713-5714-5715, is projected to fuel overall market growth in the coming years.

Based on DelveInsight’s analysis, the total number of diagnosed prevalent allergic rhinitis cases across the 7 major markets (7MM) was estimated at nearly 90 million in 2023. Japan accounted for the highest number of diagnosed cases, at approximately 26 million, and this figure is expected to rise over time. Within Europe, Germany reported the largest diagnosed allergic rhinitis population at around 10 million cases, followed by the United Kingdom with nearly 9 million cases, while Spain recorded the lowest number at approximately 5 million.

In 2023, Japan recorded approximately 26 million diagnosed prevalent allergic rhinitis cases, accounting for nearly 30% of the total burden across the 7 major markets (7MM).

According to DelveInsight’s assessment, in 2023, allergic rhinitis cases across the 7 major markets (7MM) were distributed by severity as approximately 20% mild, 60% moderate, and 20% severe. Diagnosed prevalent cases were further segmented into four age groups: 0–10 years, 10–17 years, 18–59 years, and 60 years and above. Among these, the 18–59 years age group accounted for the largest share in 2023, with nearly 60 million cases, followed by individuals aged 60 years and above, 10–17 years, and 0–10 years.

DelveInsight’s report “Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Allergic Rhinitis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Allergic Rhinitis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Allergic Rhinitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Allergic Rhinitis Market Forecast

Some of the key facts of the Allergic Rhinitis Market Report:

• Key Allergic Rhinitis Companies: Regeneron Pharmaceuticals, Allergy Therapeutics, Inmunotek, UCB Pharma, Orexo AB,  Hyloris Pharmaceuticals, Revelation Biosciences Inc., Yingu Pharmaceutical, Glenmark Specialty S.A., Pfizer, Oxagen Ltd, Idorsia Pharma, Magna Pharma, Glenmark Specialty, Bayer, and others
• Key Allergic Rhinitis Therapies: REGN5713- 5714-5715, Grass MATA MPL, MG01 + T517, Levocetirizine, BLX-028914, Bencycloquidium, Dupilumab, GSP 301 NS, PF-03654764, OC000459, ACT-129968, STAHIST, GSP 301, Azelastine hydrochloride (BAYR9258), and others
• Around 178 million common cases of Allergic Rhinitis in the 7MM and 68 million common cases in the EU4 and the UK were estimated by 2022
• Some companies have initiated clinical trials investigating new treatment options, including Regeneron Pharmaceuticals’ REGN5713-5714-5715 and Grass MATA by Allergy Therapeutics as the potential therapies lined up for forecast in the 7MM in the DelveInsight therapeutics market model
• The Allergic Rhinitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Allergic Rhinitis pipeline products will significantly revolutionize the Allergic Rhinitis market dynamics. 

Allergic Rhinitis Overview

Allergic Rhinitis is an immune system reaction to airborne allergens such as pollen, dust mites, pet dander, or mold. It causes symptoms like sneezing, runny or congested nose, itchy eyes, and watery eyes. The condition can be seasonal (hay fever) or perennial (year-round), affecting quality of life and daily activities. Management includes avoiding triggers, using antihistamines, corticosteroid nasal sprays, or immunotherapy in severe cases.

Get a Free sample for the Allergic Rhinitis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/allergic-rhinitis-market

Key Trends in Allergic Rhinitis Therapeutics Market:

• Rising adoption of immunotherapy and biologics: Allergen-specific immunotherapies (SLIT/SCIT) and biologic treatments are increasingly used for long-term disease modification, especially in moderate to severe cases where traditional antihistamines or corticosteroids are insufficient.
• Growth of OTC and self-care treatment options: Consumers are increasingly using over-the-counter antihistamines, nasal sprays, and combination products for convenient symptom relief, expanding retail pharmacy and e-commerce channels.
• Innovations in drug delivery and non-invasive therapies: Advances in user-friendly delivery systems like improved nasal sprays, dissolvable tablets, and needle-free sublingual immunotherapy are enhancing efficacy, adherence, and patient experience.
• Personalized medicine and targeted treatments: There’s a shift toward personalized approaches incorporating biologics and tailored regimens based on patient profiles, with research focusing on reducing side effects and improving long-term outcomes.
• Market expansion driven by environmental & lifestyle factors: Increasing incidence of allergic rhinitis due to pollution, climate change, and heightened awareness has driven demand for effective therapeutics globally, with strong growth in regions like Asia-Pacific.

Allergic Rhinitis Epidemiology

The Allergic Rhinitis epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Allergic Rhinitis Epidemiology Segmentation:

The Allergic Rhinitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Allergic Rhinitis
• Prevalent Cases of Allergic Rhinitis by severity
• Gender-specific Prevalence of Allergic Rhinitis
• Diagnosed Cases of Episodic and Chronic Allergic Rhinitis

Download the report to understand which factors are driving Allergic Rhinitis epidemiology trends @ Allergic Rhinitis Epidemiology Forecast

Recent Development In The Allergic Rhinitis Treatment Landscape:

• In March 2025, The National Allergy Centre of Excellence (NACE) at Murdoch Children’s Research Institute (MCRI) collaborated with 17 Australian general practices and allergy clinics to launch the ARISE trial, targeting adolescents and young adults aged 14 to 29 who suffer from hay fever, also referred to as allergic rhinitis.

Allergic Rhinitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Allergic Rhinitis market or expected to get launched during the study period. The analysis covers Allergic Rhinitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Allergic Rhinitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Allergic Rhinitis Therapies and Key Companies

• REGN5713- 5714-5715: Regeneron Pharmaceuticals
• Grass MATA MPL: Allergy Therapeutics
• MG01 + T517: Inmunotek
• Levocetirizine: UCB Pharma
• BLX-028914: Orexo AB
• Bencycloquidium: Yingu Pharmaceutical
• Dupilumab: Regeneron Pharma
• GSP 301 NS: Glenmark Specialty S.A.
• PF-03654764: Pfizer
• OC000459: Oxagen Ltd
• ACT-129968: Idorsia Pharma
• STAHIST: Magna Pharma
• GSP 301: Glenmark Specialty
• Azelastine hydrochloride (BAYR9258): Bayer

Discover more about therapies set to grab major Allergic Rhinitis market share @ Allergic Rhinitis Treatment Market

Allergic Rhinitis Market Drivers

• Rising prevalence of allergic rhinitis globally: Increasing exposure to airborne allergens, urbanization, pollution, and climate change are contributing to higher incidence rates, boosting demand for effective treatments.
• Growing awareness and improved diagnosis: More patients recognizing symptoms and seeking medical care, aided by better diagnostic tools (e.g., IgE tests), drives treatment uptake.
• Advancements in therapies and delivery options: Innovations like improved antihistamines, intranasal corticosteroids, sublingual immunotherapy, and biologics enhance efficacy and convenience, appealing to both patients and physicians.
• Expanded access through OTC and prescription channels: Wider availability of over-the-counter medications and strengthened retail/online distribution increases treatment accessibility.
• Increasing healthcare spending & supportive infrastructure: Rising healthcare expenditure and investments in allergy care infrastructure in emerging markets aid market growth.

Allergic Rhinitis Market Barriers

• Side effects and limited efficacy of some treatments: Adverse effects (e.g., drowsiness, dry mouth) and incomplete symptom relief from existing medications can reduce patient adherence.
• High cost of advanced therapies: Expensive biologics and immunotherapy treatments can limit uptake, especially where reimbursement is poor.
• Underdiagnosis and misdiagnosis: Similarity to common cold or lack of awareness particularly in developing regions hampers accurate diagnosis and appropriate treatment.
• Competition from generics and OTC self-care: Widespread use of low-cost generics and self-medication may compress pricing power for branded products and slow innovation incentives.
• Regulatory and reimbursement hurdles: Complex approval processes and uneven insurance coverage can delay product launches and limit patient access, particularly for novel therapies.

Scope of the Allergic Rhinitis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Allergic Rhinitis Companies: Regeneron Pharmaceuticals, Allergy Therapeutics, Inmunotek, UCB Pharma, Orexo AB,  Hyloris Pharmaceuticals, Revelation Biosciences Inc., Yingu Pharmaceutical, Glenmark Specialty S.A., Pfizer, Oxagen Ltd, Idorsia Pharma, Magna Pharma, Glenmark Specialty, Bayer, and others
• Key Allergic Rhinitis Therapies: REGN5713- 5714-5715, Grass MATA MPL, MG01 + T517, Levocetirizine, BLX-028914, Bencycloquidium, Dupilumab, GSP 301 NS, PF-03654764, OC000459, ACT-129968, STAHIST, GSP 301, Azelastine hydrochloride (BAYR9258), and others
• Allergic Rhinitis Therapeutic Assessment: Allergic Rhinitis current marketed and Allergic Rhinitis emerging therapies
• Allergic Rhinitis Market Dynamics: Allergic Rhinitis market drivers and Allergic Rhinitis market barriers 
• Allergic Rhinitis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Allergic Rhinitis Unmet Needs, KOL’s views, Analyst’s views, Allergic Rhinitis Market Access and Reimbursement 

To know more about Allergic Rhinitis companies working in the treatment market, visit @ Allergic Rhinitis Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.